Michael Westafer, MD
Ophthalmology · Carson City, NVNPI 1033473913
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Alcon at 25.0% of the total.
Across 121 payments — averaging $35.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$855
- NEW World Medical,inc.$843
- Aerie Pharmaceuticals, Inc.$408
- Rxsight Inc$194
- Glaukos Corporation$166
- plus $731 from 15 others
What the payments were for
- Food & beverage$4,15197%
- Education$1133%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 28 | $1,066 |
| AbbVie(2 entities) | 33 | $855 |
| NEW World Medical,inc. | 10 | $843 |
| Aerie Pharmaceuticals, Inc. | 11 | $408 |
| Rxsight Inc | 6 | $194 |
| Glaukos Corporation | 1 | $166 |
| Sun Pharmaceutical Industries Inc. | 5 | $109 |
| Sight Sciences, Inc. | 5 | $96 |
| Novartis | 4 | $75 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $68 |
| Mallinckrodt Hospital Products Inc. | 2 | $63 |
| Nova Eye, Inc. | 1 | $47 |
| E.r. Squibb & Sons, L.L.C. | 1 | $46 |
| Dompe US, Inc. | 2 | $41 |
| Thea Pharma Inc. | 2 | $40 |
| Harrow Eye, LLC | 1 | $37 |
| Ivantis, Inc | 1 | $31 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $24 |
| Rayner Intraocular Lenses Limited | 1 | $20 |
| Biotissue Holdings Inc. | 1 | $18 |
| Eyepoint US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kahook Dual Blade$777
- Clearpath$777
- Ahmed Glaucoma Valve$777
- Streamline$777
- Via360$342
- Clareon$155
- Hydrus Microstent$150
- ORA System VerifEye$122
- ARGOS$115
- DURYSTA$113
- Rhopressa$107
How this compares
$4,264 in reported general payments places this provider in the 70th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 248 | $140,909 |
| RocklatanNetarsudil Mesylat/Latanoprost | 52 | $35,793 |
| RhopressaNetarsudil Mesylate | 69 | $30,850 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 82 | $28,192 |
| Latanoprost | 2,060 | $26,024 |
| Brinzolamide | 111 | $25,058 |
| XiidraLifitegrast | 16 | $20,942 |
| RestasisCyclosporine | 16 | $19,376 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 880 | $19,350 |
| Alphagan PBrimonidine Tartrate | 34 | $17,780 |
| VyzultaLatanoprostene Bunod | 33 | $17,379 |
| Brimonidine Tartrate | 298 | $16,004 |
| CombiganBrimonidine Tartrate/Timolol | 34 | $15,894 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 46 | $15,079 |
| Travoprost | 73 | $14,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $855 | $193,959332 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $408 | $66,642121 claims |
| AlconSimbrinza, Azopt | $1,066 | $23,18457 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $68 | $10,75931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 121 ophthalmology providers in Nevada.
Other ophthalmology in Carson City
- Robert WolffCarson City$12K
- Ziqiang WuCarson City$3K
- Mehdi VazeenCarson City$2K
- Charlotte WrightCarson City$2K
- Arshad KhananiReno$2M
- Eva LiangLas Vegas$496K
- Rene ZamoraHenderson$216K
- Steven LeibowitzLas Vegas$147K
- Steve ChangReno$75K
- Curtis ManningSparks$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.